The PPD clinical research business of Thermo Fisher Scientific has announced a significant new research and development (R&D) partnership with the AstraZeneca BioVentureHub in Gothenburg, Sweden, aimed at fostering innovation and strengthening the life science ecosystem. has announced a significant new research and development (R&D) partnership with the AstraZeneca BioVentureHub in Gothenburg, Sweden, aimed at fostering innovation and strengthening the life science ecosystem.

This strategic collaboration involves a dedicated team from Thermo Fisher co-locating with AstraZeneca scientists to work on joint R&D projects, initially concentrating on crucial scientific fields such as chromatography, molecular genomics, and proteomics.

The partnership is designed as an open innovation environment, creating exceptional conditions for breakthrough discovery by providing collaborators, including emerging life sciences companies and academic groups, easy access to cutting-edge technologies. This co-location is integrated within the burgeoning Gothenburg innovation ecosystem, which includes the GoCo Health Innovation City. Complementing this R&D alliance, Thermo Fisher is currently constructing a state-of-the-art bioanalytical laboratory within the GoCo Health Innovation City, which is anticipated to become operational in March 2026. This new facility will significantly enhance Thermo Fisher's global network of laboratories by offering leading-edge bioanalytical capabilities to support all phases of pharmaceutical and biotech development for customers across Europe and around the globe, aligning with the company's core mission to enable its customers to make the world healthier, cleaner, and safer.